JP2022528915A - 腫瘍を治療することの方法 - Google Patents

腫瘍を治療することの方法 Download PDF

Info

Publication number
JP2022528915A
JP2022528915A JP2021559659A JP2021559659A JP2022528915A JP 2022528915 A JP2022528915 A JP 2022528915A JP 2021559659 A JP2021559659 A JP 2021559659A JP 2021559659 A JP2021559659 A JP 2021559659A JP 2022528915 A JP2022528915 A JP 2022528915A
Authority
JP
Japan
Prior art keywords
compound
tumor
alkyl
epoxy
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528915A5 (https=
Inventor
アン ゴードン ビクトリア
ウォーレン レデル ポール
マシュー ボイル グレン
キングスリー カレン ジェイソン
ゴードン パーソンズ ピーター
Original Assignee
キューバイオティクス プロプライアタリー リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by キューバイオティクス プロプライアタリー リミティド filed Critical キューバイオティクス プロプライアタリー リミティド
Publication of JP2022528915A publication Critical patent/JP2022528915A/ja
Publication of JP2022528915A5 publication Critical patent/JP2022528915A5/ja
Priority to JP2024231893A priority Critical patent/JP2025060945A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021559659A 2019-04-12 2020-04-09 腫瘍を治療することの方法 Pending JP2022528915A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024231893A JP2025060945A (ja) 2019-04-12 2024-12-27 腫瘍を治療することの方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901280 2019-04-12
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024231893A Division JP2025060945A (ja) 2019-04-12 2024-12-27 腫瘍を治療することの方法

Publications (2)

Publication Number Publication Date
JP2022528915A true JP2022528915A (ja) 2022-06-16
JP2022528915A5 JP2022528915A5 (https=) 2023-01-26

Family

ID=72752169

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559659A Pending JP2022528915A (ja) 2019-04-12 2020-04-09 腫瘍を治療することの方法
JP2024231893A Pending JP2025060945A (ja) 2019-04-12 2024-12-27 腫瘍を治療することの方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024231893A Pending JP2025060945A (ja) 2019-04-12 2024-12-27 腫瘍を治療することの方法

Country Status (26)

Country Link
US (1) US12226391B2 (https=)
EP (1) EP3952858B1 (https=)
JP (2) JP2022528915A (https=)
KR (1) KR20210152531A (https=)
CN (1) CN113924091A (https=)
AU (1) AU2020256847B2 (https=)
BR (1) BR112021020253A2 (https=)
CA (1) CA3136216C (https=)
DK (1) DK3952858T3 (https=)
EA (1) EA202192757A1 (https=)
ES (1) ES3063750T3 (https=)
FI (1) FI3952858T3 (https=)
HR (1) HRP20260232T1 (https=)
IL (1) IL287210B2 (https=)
LT (1) LT3952858T (https=)
MX (1) MX2021012449A (https=)
MY (1) MY208979A (https=)
PL (1) PL3952858T3 (https=)
PT (1) PT3952858T (https=)
RS (1) RS67777B1 (https=)
SG (1) SG11202110599RA (https=)
SI (1) SI3952858T1 (https=)
SM (1) SMT202600066T1 (https=)
UA (1) UA129840C2 (https=)
WO (1) WO2020206504A1 (https=)
ZA (1) ZA202108677B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597019A (en) * 2005-12-23 2013-11-29 Qbiotics Ltd Tiglien-3-one derivatives
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
IL289072B2 (en) 2019-06-19 2025-06-01 QBiotics Pty Ltd Biofilm disruption
JP2024546296A (ja) * 2021-12-21 2024-12-19 キューバイオティクス プロプライアタリー リミティド 結晶性中間体
CN120569368A (zh) * 2022-12-21 2025-08-29 Q生物股份有限公司 晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520699A (ja) * 2005-12-23 2009-05-28 キューバイオティクス リミテッド チグリエン−３−オン誘導体
JP2016522801A (ja) * 2013-04-18 2016-08-04 キューバイオティクス リミテッド 創傷治癒のための方法および組成物
WO2018170559A1 (en) * 2017-03-23 2018-09-27 Qbiotics Limited Combination therapy for the treatment or prevention of tumours
JP2019523303A (ja) * 2016-07-28 2019-08-22 キューバイオティクス リミティド 治療方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520699A (ja) * 2005-12-23 2009-05-28 キューバイオティクス リミテッド チグリエン−３−オン誘導体
JP2016522801A (ja) * 2013-04-18 2016-08-04 キューバイオティクス リミテッド 創傷治癒のための方法および組成物
JP2019523303A (ja) * 2016-07-28 2019-08-22 キューバイオティクス リミティド 治療方法
WO2018170559A1 (en) * 2017-03-23 2018-09-27 Qbiotics Limited Combination therapy for the treatment or prevention of tumours

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN VETERINARY SCIENCE, vol. 6, no. 106, JPN6023051292, 9 April 2019 (2019-04-09), pages 1 - 10, ISSN: 0005221930 *
INVESTIONAL NEW DRUGS, vol. 37, no. 1, JPN6023051293, February 2019 (2019-02-01), pages 1 - 8, ISSN: 0005221931 *
PLOS ONE, vol. Vol.9, No.10, e108887, JPN6023051294, 2014, ISSN: 0005221932 *

Also Published As

Publication number Publication date
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
IL287210B2 (en) 2025-07-01
AU2020256847A1 (en) 2021-11-11
PT3952858T (pt) 2026-02-26
IL287210B1 (en) 2025-03-01
SG11202110599RA (en) 2021-10-28
CA3136216A1 (en) 2020-10-15
CN113924091A (zh) 2022-01-11
EP3952858A1 (en) 2022-02-16
EP3952858B1 (en) 2025-12-17
ES3063750T3 (en) 2026-04-20
WO2020206504A1 (en) 2020-10-15
SMT202600066T1 (it) 2026-03-09
ZA202108677B (en) 2026-03-25
AU2020256847B2 (en) 2025-05-15
IL287210A (en) 2021-12-01
US12226391B2 (en) 2025-02-18
DK3952858T3 (da) 2026-02-23
RS67777B1 (sr) 2026-03-31
JP2025060945A (ja) 2025-04-10
MY208979A (en) 2025-06-14
HRP20260232T1 (hr) 2026-03-27
PL3952858T3 (pl) 2026-03-30
EA202192757A1 (ru) 2022-02-11
FI3952858T3 (fi) 2026-02-18
MX2021012449A (es) 2021-11-12
CA3136216C (en) 2024-01-16
EP3952858A4 (en) 2022-05-25
KR20210152531A (ko) 2021-12-15
UA129840C2 (uk) 2025-08-20
BR112021020253A2 (pt) 2021-12-07
SI3952858T1 (sl) 2026-04-30

Similar Documents

Publication Publication Date Title
JP6905075B2 (ja) 腫瘍の治療または予防のための併用療法
JP2022528915A (ja) 腫瘍を治療することの方法
JP6426706B2 (ja) がん処置で使用するためのｇｌａ単剤療法
JP2017533920A (ja) ウイルス粒子を用いた癌免疫療法
Chung et al. Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis
CN110831629A (zh) 用于治疗癌症的包括abx196的组合
KR20240148417A (ko) 조합 치료법
HK40060616B (en) Method of treating tumours
HK40060616A (en) Method of treating tumours
EA044461B1 (ru) Способ лечения опухолей
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
JP2026500734A (ja) 医薬組み合わせ、及びその使用
CN115715803A (zh) 溶瘤病毒和免疫相关药物在协同抑制实体瘤中的应用
CN116870150A (zh) Pnu112455a抑制剂和pd-1抗体联用在制备肝细胞癌免疫治疗药物中的应用
Bramante et al. 438. Oncolytic Immunotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer
Hamada et al. 437. Biosafety After the Injection of Carrier Cells Infected With Oncolytic Adenovirus
Rashmir et al. Equine Sarcoid Consensus Statement February 2026

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250108